anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
BACKGROUND: Lymph node metastasis is significantly associated with a worse prognosis in patients with localized early-stage esophageal squamous cell carcinoma. This study aimed to explore the prognostic factors and develop a nomogram for predicting survival in patients with pathologic T1-2N+ esophageal squamous cell carcinoma.
METHODS: Between 2014 and 2022, patients with pT1-2N+ esophageal squamous cell carcinoma who underwent esophagectomy with lymphadenectomy at 2 institutes were reviewed and assigned to training and external validation cohorts. Independent prognostic factors were identified via univariate and multivariate Cox regression analyses. The nomogram model was developed and evaluated by the area under the receiver operating characteristic curve and calibration curve.
RESULTS: In total, 268 patients with a median age of 65 years (range, 40-82) were included and assigned to training (n = 190) and external validation (n = 78) cohorts. The Cox proportional hazards model demonstrated that body mass index (P = .031), surgical approach (P < .001), T stage (P = .015), and Clavien-Dindo classification (P < .001) were independent prognostic factors in the training cohort. The nomogram showed good discrimination, with an area under the receiver operating characteristic curve for 1-year, 3-year, and 5-year of 0.810, 0.789, and 0.809 in the training cohort and 0.782, 0.679, and 0.698 in the validation cohort. The calibration curve showed that the predicted survival probability was in good agreement with the actual survival probability.
CONCLUSION: Lower body mass index, left surgical approach, T2 stage, and Clavien-Dindo classification grade III to V were related to worse prognosis in patients with pT1-T2N+ esophageal squamous cell carcinoma. The developed nomogram may predict individual survival accurately.
After a 2-week placebo run-in, participants received ERN/LRPT 1 g (MK-0524A) co-administered with SIM 20 mg once daily for 4 weeks then received ERN/LRPT 2 g (MK-0524A) co-administered with SIM 40 mg once daily for 8 weeks. Participants then received ERN/LRPT/SIM 2 g/40 mg combination tablets (MK-0524B) once daily for 8 weeks.
The utility model discloses a leakproofness navel subsides, including pasting main part, a PU layer, the lower extreme surface on PU layer is provided with the layer that generates heat, the upper end surface on the layer that generates heat is provided with porous cotton-padded covering, the lower extreme surface on the layer that generates heat is provided with paste the agent No. one, the lower extreme surface of pasting the agent No. one is provided with from type paper, the inside of pasting the main part is close to one side of air vent and is provided with the through-hole, the inboard of through-hole is provided with treatment medicine coating, treatment medicine coating's upper end surface is provided with medical cotton, medical cotton's the outside is provided with paste the agent No. two, medical cotton's upper end surface is provided with the gauze layer, the upper end surface of gauze layer is provided with No. two. A leakproofness navel subsides, can reduce the skin of pulling of large tracts of land, can play the effect of promoting blood circulation and removing blood stasis to near navel skin.
This is a single-center study. The study protocol, informed consents, and amendments were approved in writing by the appropriate local site Independent Ethics Committee (IEC)/Institutional Review Boards (IRB) (Ethics Committee of the Universidad Autónoma de Nuevo León, School of Medicine).

The patients were recruited as outpatients from the Geriatrics Clinic. A total of 67 patients were screened out of which 40 male and female patients diagnosed with mild to moderate dementia were recruited to the study. Following inclusion, all patients underwent randomization to treatment with melatonin (5 mg orally) or placebo for 8 weeks. To prevent bias, matching placebo tablets, which were identical in appearance, taste, and odor, were used. The treatment was double-blinded, with two parallel treatment groups. Selection for a treatment group was determined by a computer-generated randomization list, in a 1:1 ratio using the randomized permuted blocks method.
Dosages must be adjusted to each patient's needs, starting with 60 to 120 mg twice daily. Maximum antihypertensive effect is usually observed by 14 days of chronic therapy; therefore, dosage adjustments should be scheduled accordingly. Although individual patients may respond to lower doses, the usual optimum dosage range in clinical trials was 240 to 360 mg/day.

Diltiazem hydrochloride extended-release Capsules have an additive antihypertensive effect when used with other antihypertensive agents. Therefore, the dosage of diltiazem hydrochloride extended-release capsules or the concomitant antihypertensives may need to be adjusted when adding one to the other. See WARNINGS and PRECAUTIONS regarding use with beta-blockers.
PURPOSE: To obtain a stable foamable dentifrice comprising a liquid humectant vehicle and flocculated particles formed from a siliceous polishing material in the presence of a resinous poly(ethylene oxide), and capable of being easily extruded from a dentifrice tube. CONSTITUTION: This foamable dentifrice comprises 20-80wt.% of a liquid humectant vehicle (e.g. maltitol), 5-50wt.% of a siliceous polishing material (e.g. an alkali metal aluminoisilicate) and 0.05-5wt.% of a resinous poly(ethylene oxide). The dentifrice contains flocculated particles formed from the siliceous polishing material in the presence of the poly(ethylene oxide). The dentifrice is sweet and non-irritative, and does not form the carrion of oral mucosa and deteriorate the flavors of citrus fruits. The polyethylene oxide has a reduced viscosity of 0.5 in a concentration of 0.2g in 100ml of acetonitrile.
Powdered medicine compn. contg. lower alkylester of cellulose as a base, steroid or glycyrrhizic acid as a antiinflammatory, and solid organic acid as a stabilizer is prepd.  Thus, 100 part hydroxypropyl cellulose, 0.025 part beclomethasone dipropionate, and 0.5 part stearic acid is mixed thoroughly to give powd. compn., which is capsulated into tablets for oral use. Hydroxypropyl cellulose used in prepn. of the compn. has the viscosity of 1550cps in 2% aq. soln. at 37±0.2≰C and powder particles of 90% > has the particle diameter of 37-149  m.
Neither MEG(or EEG) equipment is cheap nor to classify MEG spectrum for cancer or diseases by human inspection is time-efficient. Even there is few deep learning approach for the automated predictive classification for healthcare, it needs huge devices and quantitative human inspection before abundant data is available for the deep learning. This invention creates a tractable revised deep learning for the healthy diets response of MEG spectrum for predictive classification. This invention is specially dedicated to a augmentation of the MEG spectrum sample size by mutation (such as [alpha] wave from 9Hz to 11Hz or 8Hz) on digital data. It retrieves data of MEG device spectrum from database server to digitize. It makes the best use of digitalized and generated data in categorized range for similarity before testing the similarity of dataset, and includes them into the augmented dataset for deep learning training to facilitate automated predictive classification with non-big samples.
BACKGROUND: The integration of high-risk human papilloma virus (HPV) DNA into the human genome has been implicated in cervical carcinogenesis and head and neck squamous cell cancer. However, its role in lung squamous cell carcinoma is not well understood. In addition, tuberculosis (TB) and lung cancer(LC) share similar clinical symptoms and imaging features, increasing the risk of misdiagnosis.
CASE PRESENTATION: The patient presented with a 16-month history of hemoptysis, chest pain, and occasional fatigue, without fever, chills, or history of mechanical damage or autoimmune diseases. Examination revealed normal vital signs and laboratory parameters, except for a positive interferon-gamma release assay indicating tuberculosis infection. Bronchoscopic examinations identified congestion and edema of the tracheal wall, along with a tiny lesion in the right wall of the trachea. She had been misdiagnosed with tuberculosis. However, the diagnosis of squamous cell carcinoma was eventually confirmed by endoscopic biopsy. The patient's macrogenomic second-generation sequencing (mNGS) of the bronchoscopic biopsy specimen was positive for HPV-16.The patient's sex partner tested positive for HPV-16 in penile scrapings, indicating HPV transmission through oral sex.
CONCLUSIONS: This case highlights the potential for HPV infection acquired through oral sex to lead to lung squamous cell carcinoma. It emphasizes the importance of considering HPV-associated malignancies in patients with respiratory symptoms who engage in oral sexual behaviors.
BACKGROUND: Groin hernia repair is one of the most commonly performed surgical procedures and is often performed by surgical interns and junior residents. While traditionally performed open, minimally invasive (MIS) groin hernia repair has become an increasingly popular approach. The purpose of this study was to determine the trends in MIS and open inguinal and femoral hernia repair in general surgery residency training over the past two decades.
METHODS: Accreditation Council for Graduate Medical Education (ACGME) national case log data of general surgery residents from 1999 through 2022 were reviewed. We collected means and standard deviations of open and MIS inguinal and femoral hernia repairs. Linear regression and ANOVA were used to identify trends in the average annual number of open and MIS hernia repairs logged by residents. Cases were distinguished between level of resident trainees: surgeon-chief (SC) and surgeon-junior (SJ).
RESULTS: From July 1999 to June 2022, the average annual MIS inguinal and femoral hernia repairs logged by general surgery residents significantly increased, from 7.6 to 47.9 cases (p < 0.001), and the average annual open inguinal and femoral hernia repairs logged by general surgery residents significantly decreased, from 51.9 to 39.7 cases (p < 0.001). SJ resident results were consistent with this overall trend. For SC residents, the volume of both MIS and open hernia repairs significantly increased (p < 0.001).
CONCLUSIONS: ACGME case log data indicates a trend of general surgery residents logging overall fewer numbers of open inguinal and femoral hernia repairs, and a larger proportion of open repairs by chief residents. This trend warrants attention and further study as it may represent a skill or knowledge gap with significant impact of surgical training.
Identification in a retrospective cohort of a miRNA panel associated with the development of distant metastases.The retrospective cohort consists of tumor and normal tissue obtained from breast cancer patients, stored at -80°C at the Laboratory of Oncology. Of these samples, 360 met the inclusion criteria.
In the context of advancing medical procedures, postoperative infections in cancer patients, particularly those involving multidrug-resistant organisms, have become a significant clinical concern. This study aims to comprehensively and systematically evaluate the effectiveness of infection prevention and control for multidrug-resistant organisms (MDROs) in postoperative cancer patients using Failure Mode and Effects Analysis (FMEA). This study was conducted in a tertiary A-level cancer specialty hospital in China, employing Failure Mode and Effects Analysis (FMEA) to assess the risks of hospital infections. Intervention measures were implemented for high-risk and medium-high-risk factors. Through the hospital's infection information system, data on patients who underwent surgical treatment from 2017 to 2022 were extracted. Data from 2017 to 2019 served as the control group, and data from 2020 to 2022 as the intervention group, to compare the changes in hospital infection incidence and MDRO infection incidence before and after the intervention. Categorical data were described in terms of frequency and percentage. The chi-square test was utilized for statistical inference to assess the differences in infection rates before and after the intervention. Prior to the intervention (2017-2019), the incidence rate of hospital infections was 1.66%, which decreased to 1.22% after the intervention (2020-2022), showing a statistically significant difference (χ2 = 48.83, P < 0.001). The incidence rate of MDRO infections also decreased from 1.808‰ before the intervention to 1.136‰ after the intervention, with a statistically significant difference (χ2 = 11.417, P = 0.001). This study confirms the effectiveness of the FMEA method in preventing and controlling MDRO infections in postoperative cancer patients. It highlights the practicality and value of widespread adoption of this method, particularly in the context of the COVID-19 pandemic.
The invention provides a method for preparing functional millet bran peptides. The functional millet bran peptides can be applied to preparing anti-liver injury health food and antitumor drugs. The method comprises the following steps: using millet bran as a raw material, and obtaining albumin through extraction; after ultra-filtration or dialysis for removing impurities, respectively adopting three double-enzyme hydrolysis methods, namely papain and pepsase, bacillus-subtilis neutral proteinase and pepsase and 537 acid proteinase and pepsase to hydrolyze millet bran albumin; after enzyme-killing and centrifuging hydrolysate, obtaining three millet bran peptides. The obtained peptides is ultra-filtered with an ultra-filtration membrane with the cutoff molecular weight being 1000 Da to obtain three kinds of millet bran peptides with the molecular weight lower than 1000 Da. Tests show that the three peptides play significant roles of resisting liver injury and suppressing tumor growth. A testee takes 10-30 g of millet bran peptides every day, and no side effect exists. The millet bran peptides can be applied to liver-protection health food and antitumor drugs.
Feed additive for an avian granivore comprising a malt extract comprising one or more enzymes selected from amylases, maltases, cellulases, fructanases, glucanases, xylanases, and deacetylases. The feed additive is used for: treating/preventing one or more pathogenic bacteria, e.g gastrointestinal pathogenic bacteria such as Escherichia coli, Salmonella enteritidis, Campylobacter spp, and Staphylococcus spp, with or without the combination of a further antibiotic; reducing viral infections; reducing post-race recovery time for Columba livia domestica; improving energy utilisation, improving voluntary feed intake; increasing egg weight; increasing eggshell thickness; improving feed conversion ratio; and increasing the firmness of avian granivore droppings. The malt extract may additionally comprise: proteinases; lipases; and water soluble sugars selected from maltose, maltotriose, and maltose polymers. The malt extract may be based on the seeds of barley, wheat, triticale, sorghum, maize, buck wheat, and rice. The feed additive may additionally comprise: medium chain triglycerides e.g. coconut oil; water soluble organic acids or salts thereof e.g. caprylic acid, sorbic acid, caproic acid, benzoic acid, ascorbic acid, propionic acid, acetic acid, formic acid, fumaric acid, tartaric acid. The feed additive may be used in combination with granivore feed and the avian granivore may be Columba livia domestica or Gallus gallus domestica.
FIELD: organic chemistry, pharmacy. SUBSTANCE: invention describes novel derivatives of indoline-2-one of the formula (I)   where W means the group -CH 2 - or SO 2 ; Cy in common with carbon atom to which it is bound form nonaromatic saturated hydrocarbon cycle with 3-6 carbon atoms; T means alkylene with 1-4 carbon atoms or a simple bond; Z means amino-group; R 1 ,R 2 ,R 3  and R 4  are hydrogen atom or substituents, for example, halogen atom, alkyl and so on. New derivatives show affinity for receptors of vasopressin and/or oxytocin and can be used as active components of pharmaceutical compositions. Invention describes also method of their synthesis and pharmaceutical compositions containing thereof. EFFECT: new compounds indicated above, valuable pharmacological properties. 17 cl, 2 tbl, 54 ex
The lower age limit for the clinical trial was initially set to 3 years of age in the protocol. The trial planned for the inclusion of participants in three age categories. Age 3 to less than 6 years (young children), age 6 to less than 12 years (older children) and age 12 to less than 18 years of age (adolescents). There was a request by the Paediatric Committee (PDCO) at the European Medicines Agency to include participants 2 years of age (very young children). The protocol amendment thus planned to combine the two youngest age groups into a single reporting group. The protocol amendment only planned that the very young children group would have separate analysis for the Faces Pain Scale Revised (FPS-R) Scale and for the presentation of the serum concentrations, because the pharmacokinetic sampling scheme used in the 2 year old participants was different from the young children group (aged 3 to less than 6 years).
Thirty participants will be allocated to the arm. These interventions will terminate until 3 months from registration for each participant.
Corticosteroid injection is routinely given for treating carpal tunnel syndrome. The objective of this study is to evaluate the efficacy of ultrasound guided corticosteroid injection in reducing symptoms caused by carpal tunnel syndrome.

In this randomised clinical trial, 50 patients with both a clinical and electromyographic diagnosis of mild to moderate carpal tunnel syndrome will be recruited from the Centre Hospitalier Universitaire de Sherbrooke (CHUS). Subjects will be randomised to ultrasound guided or blind injection groups. All subjects will receive 40 mg of methylprednisolone. The primary outcome will be the Boston Carpal Tunnel Syndrome Questionnaire - Symptom Severity Scale at baseline and 3 months post injection. Both subjects and assessors will be blinded.
Idiopathic pulmonary fibrosis (IPF) is a fatal and insidious interstitial lung disease. So far, there are no effective drugs for preventing the disease process. Cellular senescence plays a critical role in the development of IPF, with the senescence and insufficient mitophagy of alveolar epithelial cells being implicated in its pathogenesis. Tetrandrine is a natural alkaloid which is now produced synthetically. It was known that the tetrandrine has anti-fibrotic effects, but the efficacy and mechanisms are still not well evaluated. Here, we reveal the roles of tetrandrine on AECs senescence and the antifibrotic effects by using a bleomycin challenged mouse model of pulmonary fibrosis and a bleomycin-stimulated mouse alveolar epithelial cell line (MLE-12). We performed the β-galactosidase staining, immunohistochemistry and fluorescence to assess senescence in MLE-12 cells. The mitophagy levels were detected by co-localization of LC3 and COVIX. Our findings indicate that tetrandrine suppressed bleomycin-induced fibroblast activation and ultimately blocked the increase of collagen deposition in mouse model lung tissue. It has significantly inhibited the bleomycin-induced senescence and senescence-associated secretory phenotype (SASP) in alveolar epithelial cells (AECs). Mechanistically, tetrandrine suppressed the decrease of mitochondrial autophagy-related protein expression to rescue the bleomycin-stimulated impaired mitophagy in MLE-12 cells. We revealed that knockdown the putative kinase 1 (PINK1) gene by a short interfering RNA (siRNA) could abolish the ability of tetrandrine and reverse the MLE-12 cells senescence, which indicated the mitophagy of MLE-12 cells is PINK1 dependent. Our data suggest the tetrandrine could be a novel and effective drug candidate for lung fibrosis and senescence-related fibrotic diseases.
Ozanimod will be started 6-12 months after the last anti-CD20 infusion or 30-180 days from their last ofatumumab injection. Ozanimod will be provided by the study.
A system for generating recombinant, human parainfluenza virus, particularly infectious, recombinant, human parainfluenza virus type 3(HPIV-3) is provided. In one embodiment, the system comprises a clone comprising a nucleotide sequence that encodes a full-length, positive sense, anti-genome of HPIV, and at least one support clone comprising a nucleotide sequence that encodes the HPIV P protein and the HPIV L protein. In another embodiment, the system further comprises a support clone which comprises a nucleotide sequence that encodes the HPIV NP protein. The present invention also provides a clone which comprises a nucleotide sequence encoding the full-length, positive sense, anti-genome of HPIV-3. The clone also comprises an RNA polymerase promoter operatively linked to the HPIV-3 antigenome-encoding sequence. In a preferred embodiement, the clone further comprises a nucleotide sequence which encodes a ribozyme immediately downstream from the sequence encoding the HPIV-3 anti-genome. The present invention also relates to a method of preparing recombinant HPIV-3 virus having site-specific mutations in the HPIV-3 genome. The method comprises preparing a clone comprising a modified HPIV-3 antigenome-encoding sequence; introducing the modified HPIV-3 clone and support clones which comprise nucleotide sequences encoding an HPIV-3 P protein, an HPIV-3 L protein, and, preferably, an HPIV-3 NP protein into host cells; and culturing the host cells under conditions that allow for synthesis of the modified HPIV-3 antigenome and the L, P, and NP proteins of HPIV-3.
Participants with recurrent craniopharyngioma will receive one (1) dose of Tovorafenib within 7 days +/- 2 days prior to planned biopsy or resection. At completion of biopsy or resection, participants having undergone biopsy only or STR or NTR will continue on combination maintenance therapy of nivolumab given every 2 weeks and Tovorafenib once weekly at the respected RP2D for each agent.
The invention relates to fusion protein with double functions of inhibiting revascularization of a tumor microenvironment and activating adaptive immune response, and a gene and application thereof. The invention discloses a group of recombinant protein with Tumstatin and CD137L double functions, and is characterized in that the protein is formed by fusing Tumstatin active segment amino acid sequence (one of SEQ ID NO. 52 to SEQ ID NO. 55) and CD137L extracellular domain protein segment amino acid sequence (one of SEQ ID NO. 64 to SEQ ID NO. 66) through flexible connecting peptide. The protein and the protein coding gene can be applied to research and application of tumor angiogenesis inhibitors, various oncology related diseases and body immunity adjusting medicines.